Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I irinotecan + cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer
NL-OMON23572Phase 1Active, not recruiting
- Sponsor
- Erasmus MC Department of Medical Oncology
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan and cisplatin in small cell lung cancer (SCLC), sponsored by Erasmus MC Department of Medical Oncology. Primary endpoints: Dose-limiting toxicity and Maximum tolerated dose. Started Jan 2003; status: active, not recruiting.
02
Drugs
irinotecancisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON23572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23572.